Targeting NFE2L2/KEAP1 mutations in advanced NSCLC with the TORC1/2 inhibitor TAK-228.

被引：1
|
作者：
Paik, Paul K.
Ahn, Linda Su Hyun
Ginsberg, Michelle S.
Plodkowski, Andrew J.
Kim, Rachel
Doyle, L. Austin
Rudin, Charles M.
机构：
[1] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[2] Mt Sinai Med Ctr, Palisades Pk, NJ USA
[3] Greenbaum Canc Ctr, Baltimore, MD USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
9085
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Targeting NFE2L2/KEAP1 Mutations in Advanced NSCLC With the TORC1/2 Inhibitor TAK-228
    Paik, Paul K.
    Fan, Pang-Dian
    Qeriqi, Besnik
    Namakydoust, Azadeh
    Daly, Bobby
    Ahn, Linda
    Kim, Rachel
    Plodkowski, Andrew
    Ni, Ai
    Chang, Jason
    Fanaroff, Rachel
    Ladanyi, Marc
    de Stanchina, Elisa
    Rudin, Charles M.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (04) : 516 - 526
  • [2] Targeting NFE2L2 mutations in advanced squamous cell lung cancers with the TORC1/2 inhibitor TAK228.
    Paik, Paul K.
    Qeriqi, Besnik
    Ahn, Linda Su Hyun
    Ginsberg, Michelle S.
    Tandon, Nidhi
    McFarland, Daniel
    Doyle, L. Austin
    de Stanchina, Elisa
    Rudin, Charles M.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [3] Targeting NFE2L2 Mutations in Advanced Squamous Cell Lung Cancers with the TORC1/2 Inhibitor TAK-228
    Paik, P.
    Ahn, L.
    Ginsberg, M.
    Mcfarland, D.
    Doyle, L.
    Rudin, C.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S816 - S816
  • [4] KEAP1/NFE2L2 Pathway Signature Outperforms KEAP1/NFE2L2 Mutation Status and Reveals Alternative Pathway-Activating Mutations in NSCLC
    Arolt, Christoph
    Dugan, Margaret
    Wild, Robert
    Richartz, Vanessa
    Holz, Barbara
    Scheel, Andreas H.
    Braegelmann, Johannes
    Wagener-Ryczek, Svenja
    Merkelbach-Bruse, Sabine
    Wolf, Juergen
    Buettner, Reinhard
    Catanzariti, Luigi
    Fler, Matthias Schef
    Hillmer, Axel M.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : 1550 - 1567
  • [5] Phase II study of TAK228 in patients with advanced non-small cell lung cancer (NSCLC) harboring NFE2L2 and KEAP1 mutations.
    Paik, Paul K.
    Ahn, Linda Su Hyun
    Plodkowski, Andrew J.
    Fan, Pang-Dian
    Rudin, Charles M.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [6] KEAP1/NRF2 (NFE2L2) mutations in NSCLC-Fuel for a superresistant phenotype?
    Dempke, Wolfram C. M.
    Reck, Martin
    LUNG CANCER, 2021, 159 : 10 - 17
  • [7] KEAP1/NFE2L2 Transcriptomic Signature Predicts Survival in Advanced Stage NSCLC Patients Without Actionable Driver Mutations
    Scheffler, M.
    Dugan, M.
    Saleh, M. M.
    Koleczko, S.
    Bragelmann, J.
    Arolt, C.
    Nogova, L.
    Riedel, R.
    Michels, S.
    Eisert, A.
    Fischer, R.
    Scharpenseel, H.
    Weber, J. P.
    Scheel, A. H.
    Merkelbach-Bruse, S.
    Buttner, R.
    Lafleur, F.
    Wild, R.
    Catanzariti, L.
    Hillmer, A. M.
    Wolf, J.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S451 - S452
  • [8] NRF2 Pathway Signature Predicts KEAP1/NFE2L2 Mutations and Reveals Alternative Pathway-Activating Mutations in NSCLC
    Arolt, C.
    Dugan, M.
    Wild, R.
    Richartz, V.
    Holz, B.
    Scheel, A. H.
    Braegelmann, J.
    Merkelbach-Bruse, S.
    Wolf, J.
    Buettner, R.
    Lafleur, F.
    Scheffler, M.
    Catanzariti, L.
    Hillmer, A.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S411 - S412
  • [9] Association of NFE2L2 and KEAP1 haplotypes with amyotrophic lateral sclerosis
    Bergstrom, Petra
    von Otter, Malin
    Nilsson, Staffan
    Nilsson, Ann-Charloth
    Nilsson, Michael
    Andersen, Peter M.
    Hammarsten, Ola
    Zetterberg, Henrik
    AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEGENERATION, 2014, 15 (1-2) : 130 - 137
  • [10] Integrated analysis of patients with KEAP1/NFE2L2/CUL3 mutations in lung adenocarcinomas
    Jin, Xing
    Zheng, Yuansheng
    Chen, Zhencong
    Wang, Fei
    Bi, Guoshu
    Li, Ming
    Liang, Jiaqi
    Sui, Qihai
    Bian, Yunyi
    Hu, Zhengyang
    Qiao, Yulei
    Xu, Songtao
    CANCER MEDICINE, 2021, 10 (23): : 8673 - 8692
12345